Prelude Therapeutics (PRLD) Earnings Date & Reports

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

PRLD is expected to report earnings to rise 13.50% to -47 cents per share on August 13

Prelude Therapeutics PRLD Stock Earnings Reports

Q2'25

Est.

$-0.48

Q1'25

Beat

by $0.01

Q4'24

Beat

by $0.10

Q3'24

Beat

by $0.04

Q2'24

Missed

by $0.04

The last earnings report on May 06 showed earnings per share of -41 cents, beating the estimate of -42 cents. With 368.02K shares outstanding, the current market capitalization sits at 56.46M.

View a ticker or compare two or three

Compare

PRLD